当前位置: 首页 >> 检索结果
25. Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.
作者: Peter Hanlon.;Elaine Butterly.;Lili Wei.;Heather Wightman.;Saleh Ali M Almazam.;Khalid Alsallumi.;Jamie Crowther.;Ryan McChrystal.;Heidi Rennison.;Katherine Hughes.;Jim Lewsey.;Robert Lindsay.;Stuart McGurnaghan.;John Petrie.;Laurie A Tomlinson.;Sarah Wild.;Amanda Adler.;Naveed Sattar.;David M Phillippo.;Sofia Dias.;Nicky J Welton.;David A McAllister.
来源: JAMA. 2025年333卷12期1062-1073页
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors improve hyperglycemia, and SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACEs) among individuals with type 2 diabetes. It is not clear whether efficacy varies by age or sex.
27. A Unified Approach to Health Data Exchange: A Report From the US DHHS.
作者: Ali B Abbasi.;Jennifer Layden.;William Gordon.;Susan Gregurick.;Nancy DeLew.;Jordan Grossman.;Arlene S Bierman.;Susan Monarez.;Lesley H Curtis.;Abigail H Viall.;Mitra Rocca.;Donna R Rivera.;Hilary Marston.;Alexandra Mugge.;Scott R Smith.;Katherine Bent.;James Macrae.;Ann Sheehy.;Renee D Wegrzyn.;R Burciaga Valdez.;Carole Johnson.;Laina Bush.;Jonathan Blum.;Mandy K Cohen.;Monica M Bertagnolli.;Robert M Califf.;Micky Tripathi.
来源: JAMA. 2025年333卷12期1074-1079页
Health information technology, such as electronic health records (EHRs), has been widely adopted, yet accessing and exchanging data in the fragmented US health care system remains challenging. To unlock the potential of EHR data to improve patient health, public health, and health care, it is essential to streamline the exchange of health data. As leaders across the US Department of Health and Human Services (DHHS), we describe how DHHS has implemented fundamental building blocks to achieve this vision.
36. 2024 Update of the RECOVER-Adult Long COVID Research Index.
作者: Linda N Geng.;Kristine M Erlandson.;Mady Hornig.;Rebecca Letts.;Caitlin Selvaggi.;Hassan Ashktorab.;Ornina Atieh.;Logan Bartram.;Hassan Brim.;Shari B Brosnahan.;Jeanette Brown.;Mario Castro.;Alexander Charney.;Peter Chen.;Steven G Deeks.;Nathaniel Erdmann.;Valerie J Flaherman.;Maher A Ghamloush.;Paul Goepfert.;Jason D Goldman.;Jenny E Han.;Rachel Hess.;Ellie Hirshberg.;Susan E Hoover.;Stuart D Katz.;J Daniel Kelly.;Jonathan D Klein.;Jerry A Krishnan.;Joyce Lee-Iannotti.;Emily B Levitan.;Vincent C Marconi.;Torri D Metz.;Matthew E Modes.;Janko Ž Nikolich.;Richard M Novak.;Igho Ofotokun.;Megumi J Okumura.;Sairam Parthasarathy.;Thomas F Patterson.;Michael J Peluso.;Athena Poppas.;Orlando Quintero Cardona.;Jake Scott.;Judd Shellito.;Zaki A Sherif.;Nora G Singer.;Barbara S Taylor.;Tanayott Thaweethai.;Monica Verduzco-Gutierrez.;Juan Wisnivesky.;Grace A McComsey.;Leora I Horwitz.;Andrea S Foulkes.; .
来源: JAMA. 2025年333卷8期694-700页
Classification of persons with long COVID (LC) or post-COVID-19 condition must encompass the complexity and heterogeneity of the condition. Iterative refinement of the classification index for research is needed to incorporate newly available data as the field rapidly evolves.
38. Adenoma Detection Rates by Physicians and Subsequent Colorectal Cancer Risk.
作者: Nastazja D Pilonis.;Piotr Spychalski.;Mette Kalager.;Magnus Løberg.;Paulina Wieszczy.;Joanna Didkowska.;Urszula Wojciechowska.;Jaroslaw Kobiela.;Jaroslaw Regula.;Thomas Rösch.;Michael Bretthauer.;Michal F Kaminski.
来源: JAMA. 2025年333卷5期400-407页
Patients of physicians with higher adenoma detection rates (ADRs) during colonoscopy have lower colorectal cancer (CRC) risk after screening colonoscopy (ie, postcolonoscopy CRC). Among physicians with an ADR above the recommended threshold, it is unknown whether improving ADR is associated with a lower incidence of CRC in their patients.
39. Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
作者: Li Chen.;Hui Li.;Hao Zhang.;Huawei Yang.;Jun Qian.;Zhihua Li.;Yu Ren.;Shu Wang.;Peifen Fu.;Hongjian Yang.;Yunjiang Liu.;Jing Sun.;Jianyun Nie.;Ruiwen Lei.;Yongzhong Yao.;Anqin Zhang.;Shouman Wang.;Xiaopeng Ma.;Zhong Ouyang.;Hongwei Yang.;Song-Yang Wu.;Shuo-Wen Cao.;Kun Wang.;Aimei Jiang.;Quchang Ouyang.;Da Pang.;Limin Wei.;Xiaoming Zha.;Yu Shen.;Xiangwen Qu.;Fei Wu.;Xiaoyu Zhu.;Zhonghua Wang.;Lei Fan.;Zhi-Ming Shao.
来源: JAMA. 2025年333卷8期673-681页
Preferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum. Blockade of the programmed death receptor 1/ligand-1 (PD-1/PD-L1) pathway may improve efficacy of classic neoadjuvant chemotherapy. Camrelizumab, an anti-PD-1 antibody, has showed antitumor activity in advanced triple-negative breast cancer.
|